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S U M M A R Y
Objectives: The SA14-14-2 Japanese encephalitis (JE) live attenuated vaccine is licensed for use only in
China, and has provided excellent efﬁcacy in reducing the incidence of JE. The humoral immune response
related to the JE vaccination has been well characterized, however cellular immune responses are less
well known.
Methods: Thirty-four healthy males who had recently received inoculation with the SA14-14-2 live
attenuated vaccine were recruited. Serum samples from these subjects were analyzed for cytokine and
chemokine levels using the FlowCytomix method.
Results: Eighteen of 34 subjects were positive for JE virus-speciﬁc IgG antibodies. Levels of interleukin
(IL)-8, monocyte chemoattractant protein (MCP)-1, macrophage inﬂammatory protein (MIP)-1a, and
MIP-1b were signiﬁcantly higher in the vaccinees than in a control group (p < 0.0001, p < 0.0001,
p = 0.021, and p < 0.0001, respectively). IL-6 was detectable in 64.7% of vaccinees, but was not detectable
in any of the controls. IL-1b, IL-2, IL-4, IL-5, IL-9, IL-10, IL-12p70, IL-13, IL-17A, IL-22, tumor necrosis
factor (TNF)-a, and interferon (IFN)-g were detected in very few subjects or were undetectable in both
groups.
Conclusions: IL-6, IL-8, MCP-1, MIP-1a, and MIP-1b may play important roles in the immune response to
JE live attenuated vaccine.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Japanese encephalitis (JE) is prevalent in eastern and southern
Asia. An estimated three billion persons live in areas where JE is
endemic, and the annual incidence of the disease in these areas is
30 000–50 000 cases.1 Approximately 25–30% of cases are fatal,
and 50% result in irreversible neuropsychiatric sequelae. In China,
JE is the most important viral encephalitis and is one of four
currently circulating arbovirus diseases.2 After a nationwide
vaccination program was initiated in the late 1970s, the incidence
of JE dramatically decreased.3 Both inactivated and live attenuated
JE vaccines have been developed in China.4 The inactivated vaccine
was introduced in the mid-1970s and played a major role in
reducing the incidence of JE in the 1980s and 1990s. The SA14-14-2
JE live attenuated vaccine, developed and licensed for use only in
China in 1988, provides excellent efﬁcacy and has replaced the
inactivated vaccine in many provinces.5–7
The humoral immune response related to JE vaccination has
been well characterized in humans and in animal models,8–10* Corresponding author. Tel.: +86 10 63896082; fax: +86 10 63896082.
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are less well known. Studies on the immune response related to
cytokine action during JEV infection have shown that various
proinﬂammatory mediators like interferon (IFN)-a, tumor necrosis
factor (TNF), interleukin (IL)-6, IL-8, and RANTES (regulated upon
activation, normal T-cell expressed and secreted) are associated
with the severity of JE disease.11–13 There is less information with
respect to serum patterns of cytokines and chemokines in JE
vaccination or unapparent JEV infection in both humans and
experimental animals. The present study investigated cytokine
and chemokine responses in human recipients of SA14-14-2 live
attenuated vaccine.
2. Materials and methods
2.1. Subjects and sample collection
Thirty-four healthy males (mean  standard deviation (SD) age,
31.9  6.7 years) without any acute or chronic infectious diseases
were recruited at a medical examination and formed the study
population. They had received a single-dose inoculation of JE live
attenuated vaccine (The Lanzhou Institute of Biological Products,
Lanzhou, China) 20 days prior to presentation, but no otherses. Published by Elsevier Ltd. All rights reserved.
Table 1
Cytokine secretion in serum from JE-vaccinated subjects and controls
Vaccinee (n = 34) Control (n = 16)
Detected, No. Percentage Detected, No. Percentage
IL-1b 2 5.9% 1 6.3%
IL-2 1 2.9% Not detected -
IL-4 Not detected - 1 6.3%
IL-5 1 2.9% Not detected -
IL-6 22 64.7% Not detected -
IL-9 1 2.9% Not detected -
IL-10 Not detected - Not detected -
IL-12p70 2 5.9% Not detected -
IL-13 1 2.9% Not detected -
IL-17A Not detected - 1 6.3%
IL-22 Not detected - 4 25%
TNF-a 9 26.5% 3 18.8%
IFN-g Not detected - Not detected -
JE, Japanese encephalitis; IL, interleukin; TNF, tumor necrosis factor; IFN, interferon.
Table 2
Chemokine secretion in serum from JE-vaccinated subjects and controls
Vaccinee (n = 34) Control (n = 16)
Detected, No. Percentage Detected, No. Percentage
IL-8 34 100%a 7 43.8%
MCP-1 34 100% 12 75%
MIP-1a 33 97.1% 11 68.8%
MIP-1b 33 97.1% 11 68.8%
MIG 33 97.1% 11 68.8%
G-CSF 1 2.9% 3 18.8%
JE, Japanese encephalitis; IL, interleukin; MCP, monocyte chemoattractant protein;
MIP, macrophage inﬂammatory protein; MIG, monokine induced by interferon-
gamma; G-CSF, granulocyte colony stimulating factor.
a p < 0.0001.
Table 3
IL-6 and chemokine levels (pg/ml) in serum from JE-vaccinated subjects and
controls
Vaccinee (n = 34) Control (n = 16) p-Valuea
Median IQR Median IQR
IL-6 13.5 0.0–94.9 - - -
IL-8 1034.2 457.7–2142.8 5.1 0.0–40.2 <0.0001
MCP-1 386.9 260.5–529.8 108.7 70.2–188.6 <0.0001
MIP-1a 517.8 271.9–1333.7 256.2 75.7–612.0 0.021
MIP-1b 324.5 143.6–679.7 57.9 27.4–106.0 <0.0001
MIG 145.2 83.8–213.2 84.5 45.9–190.6 0.116
JE, Japanese encephalitis; IQR, interquartile range; IL, interleukin; MCP, monocyte
chemoattractant protein; MIP, macrophage inﬂammatory protein; MIG, monokine
induced by interferon-gamma.
a Non-parametric test.
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were recruited as controls; they had no history of vaccination, or of
acute or chronic infections, within the last 6 months. The mean age of
vaccinated subjects was signiﬁcantly higher than that of the controls.
Serum samples from all participants were collected and stored at
80 8C until use.
2.2. JEV-speciﬁc antibody detection
JEV-speciﬁc immunoglobulin (Ig) M and IgG antibodies from
serum were measured by IgM antibody-capture ELISA (MAC-
ELISA) and indirect ELISA (Shanghai B & C Enterprise Development
Co. Ltd, Shanghai, China), respectively.
2.3. Measurement of cytokines and chemokines
Serum cytokines IL-1b, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-
12p70, IL-13, IL-17A, IL-22, IFN-g, and TNF-a, and chemokines IL-
8, monocyte chemoattractant protein (MCP)-1, macrophage
inﬂammatory protein (MIP)-1a, MIP-1b, monokine induced by
interferon-g (MIG), and granulocyte colony stimulating factor (G-
CSF), were analyzed using a FlowCytomixTM kit (Bender MedSys-
tems, Vienna, Austria), in accordance with the manufacturer’s
instructions. Brieﬂy, beads that had distinct ﬂuorescence intensi-
ties and that had been coated with speciﬁc capturing antibodies
were incubated with the serum sample. The cytokine/chemokine-
captured beads were then mixed and inoculated with phycoery-
thrin-conjugated detection antibodies. Fluorescence intensities
were detected on a FACSCalibur ﬂow cytometer using CellQuest
Pro software (BD Biosciences). Based on a standard curve, analysis
was performed using FlowCytomix Pro (version 2.3) software
(Bender MedSystems). The thresholds of detection were as follows:
1.2 pg/ml for IL-6; 1.5 pg/ml for IL-9 and IL-12p70; 1.6 pg/ml for
IFN-g and IL-5; 1.9 pg/ml for IL-10; 2.5 pg/ml for IL-17A; 3.2 pg/ml
for TNF-a; 4.2 pg/ml for IL-1b; 4.5 pg/ml for IL-13; 16.4 pg/ml for
IL-2; 20.8 pg/ml for IL-4; 43.3 pg/ml for IL-22; 0.9 pg/ml for MIG;
1.0 pg/ml for MIP-1a and MIP-1b; 2.2 pg/ml for IL-8 and MCP-1;
and 3.4 pg/ml for G-CSF.
2.4. Statistical analysis
Group differences in frequency were tested with the Chi-square
test. The Mann–Whitney U-test was used for comparing the levels
of cytokines and chemokines between vaccinees and controls
because of the non-parametric distribution of data and the
relatively small number of observations. All analyses were
performed using SPSS v.11.5 software. p-Values of <0.05 were
considered to indicate statistical signiﬁcance. Two-sided p-values
are given.
3. Results
Of all 13 cytokines measured, only IL-6 showed a higher
detectable rate (64.7%) in the vaccinated subjects; IL-6 was not
detectable in any of the controls. TNF-a was positively detected in
26.5% of vaccinees and in 18.8% of controls. IL-1b, IL-2, IL-4, IL-5, IL-
9, IL-10, IL-12p70, IL-13, IL-17A, and IFN-g were detected in very
few subjects or were undetectable in both groups. IL-22 was
positive in four of 16 controls, but was undetectable in all
vaccinees (Table 1).
In contrast with the cytokines, chemokines IL-8, MCP-1, MIP-
1a, MIP-1b, and MIG had high percentages of detectable levels in
the vaccinated subjects (97–100%) and controls (44–75%), while
one of 34 vaccinees and three of 16 controls had detectable G-CSF
(Table 2). The detectable rate of IL-8 in the vaccinated group was
signiﬁcantly higher than that in the controls (p < 0.0001). Therewere no signiﬁcant differences in the detectable rate between the
two groups for the other chemokines.
IL-6 and chemokine levels in vaccinated subjects and controls
are shown in Table 3. Levels of IL-8, MCP-1, MIP-1a, and MIP-1b
were signiﬁcantly higher in vaccinated subjects than those in
controls. The median MIG level was higher in vaccinees than that in
controls, but the difference did not reach statistical signiﬁcance
(p = 0.116). No signiﬁcant correlation of IL-6 and the chemokines
with age was found.
Only one subject was IgM-positive. Eighteen (52.9%) of 34
subjects were positive for IgG antibodies. There were no signiﬁcant
differences in any of the cytokines or chemokines detected
between IgG-positive and IgG-negative vaccinees.
4. Discussion
Our results demonstrate that serum cytokine IL-6 and
chemokines IL-8, MCP-1, MIP-1a, and MIP-1b were elevated in
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cytokines studied, including IL-1b, IL-2, IL-4, IL-5, IL-9, IL-10, IL-
12p70, IL-13, IL-17A, IL-22, TNF-a, and IFN-g, were detected in
very few subjects or were undetectable in the two groups.
Chemokines are divided into four subfamilies (CC, CXC, CX 3 C,
and C) on the basis of the arrangement and number of positionally
conserved cysteine motifs. MCP-1 (CCL2), MIP-1a (CCL3), and MIP-
1b (CCL4) belong to the CC subfamily. They are the major
chemoattractants for monocytes during the inﬂammatory re-
sponse, whereas CXC chemokine IL-8 (CXCL8) commonly attracts
and activates neutrophil leukocytes.14,15 MCP-1, MIP-1a, and MIP-
1b were found to be expressed in some central nervous system
(CNS) infections and to play a protective or immunopathological
role in the host immune response.16–18 Following JEV infection,
MCP-1 or MCP-1 mRNA was mainly detected in microglia and
astrocytes and related to neuronal death.19 Few studies have
indicated the role of these chemokines in the immune response to
JEV in the periphery, especially in the human population. Levels of
serum MCP-1 were reported to be increased in patients with live
attenuated yellow fever vaccine-associated viscerotropic dis-
ease.20 These ﬁndings have also been reported in rat serum with
non-lethal wild-type JEV infection.21 A signiﬁcant correlation
between viral replication and the MCP-1 or MIP-1a level has been
suggested in several virus infections in vitro and in vivo.22,23 Our
observations of high levels of MCP-1, MIP-1a, and MIP-1b in the
vaccinees may be a result of SA14-14-2 strain replication in serum.
IL-6 and IL-8 are believed to contribute to the antiviral response
indirectly by modulating various aspects of the immune
response.24 In a study on JE patients, IL-6 and IL-8 were
signiﬁcantly higher in the cerebrospinal ﬂuid of non-survivors
compared to survivors.12 Similarly, there were elevated levels of IL-
6 and IL-8 in the cerebrospinal ﬂuid in viral encephalitis compared
to controls.25 A signiﬁcantly higher serum IL-8 concentration was
detected in acute JE patients than in convalescent patients or
healthy controls, and a good correlation was shown between IL-8
and neutrophil count, which has been suggested to relate to JEV
degradation.26,27 There were increased levels of IL-6 in the serum
of rats during non-lethal JEV infection.21
Our results indicate that the cytokine proﬁle induced by SA14-
14-2 live attenuated vaccine in the human differs from that caused
by wild-type JEV. In the present study, serum IL-4, IL-10, IL-17A, IL-
22, and IFN-g were not detected in any of the vaccinees, and IL-1b,
IL-2, IL-5, IL-9, IL-12p70, IL-13, and TNF-a were detected in very
few. Conversely, higher percentages of JE patients with detectable
IFN-g and IL-4 in plasma have been observed.12 These discre-
pancies may be due to differences in sampling time. In this study,
collection of the serum sample was conducted at 20 days post-
vaccination, whereas the patients tended to present earlier to the
hospital, generally within 7 days after the onset of illness. The
association of cytokine secretion with sampling time has been
indicated in animal models. During unapparent JEV infection by
non-neuroinvasive JEV in mice, TNF-a, IL-4, and IL-10 were found
to be signiﬁcantly increased within 5 days post-inoculation (dpi),
but decreased to the levels before infection at 7 dpi.28 Similarly, in
JEV-infected rats, the serum levels of cytokines TNF-a, IFN-g, IL-4,
and IL-10 increased gradually only within 10 dpi, but signiﬁcantly
increased IL-6 and MCP-1 levels continued to 20 dpi.21 Other
possibilities are differences in species (murine vs. human) or viral
dose and strain (wild-type strain vs. vaccine strain). In addition, a
limitation of this study is that only a single time-point was used for
serum sampling. Other cytokines or chemokines may have been
produced and may play an important role in immunity, but were
missed.
In conclusion, proinﬂammatory cytokine IL-6 and chemokines
IL-8, MCP-1, MIP-1a, and MIP-1b may play important roles in the
immune response to SA14-14-2 live attenuated vaccine in thehuman. Further investigations based on multiple samplings are
necessary.
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